EGFR and non-small cell lung carcinoma: <h4>Background</h4>Non-small cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor exon 20 (EGFR Ex20Ins) is rare and resistant to conventional tyrosine kinase inhibitors (TKIs), limiting treatment options.